(Q35557363)

8 August 2017

1 reference

title

Insulin resistance: from predisposing factor to therapeutic target in type 2 diabetes (English)

1 reference

8 August 2017

Insulin resistance: From predisposing factor to therapeutic target in type 2 diabetes (English)

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(03)80242-4

20 March 2024

1 reference

1 reference

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(03)80242-4

20 March 2024

author name string

Robert R. Henry

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14553866

20 March 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14553866

20 March 2024

publication date

1 January 2003

1 reference

full work available at URL

8 August 2017

https://api.elsevier.com/content/article/PII:S0149291803802424?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(03)80242-4

https://api.elsevier.com/content/article/PII:S0149291803802424?httpAccept=text/plain

20 March 2024

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(03)80242-4

20 March 2024

published in

Clinical Therapeutics

1 reference

8 August 2017

25 Suppl B

1 reference

8 August 2017

B47-63

1 reference

Pathogenesis of NIDDM. A balanced overview

8 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

Insulin resistance: current concepts

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

Abdominal adiposity and insulin resistance in obese men.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

The genetic basis of type 2 diabetes mellitus: impaired insulin secretion versus impaired insulin sensitivity.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

Drug-induced disorders of glucose tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

Endothelial dysfunction in endocrine disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

Insulin resistance: definition and consequences

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

Pathophysiology of insulin resistance in human disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

1 reference

7 January 2021

The metabolic syndrome influences the risk of chronic complications in patients with type II diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

The syndromes of insulin resistance and acanthosis nigricans. Insulin-receptor disorders in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

Acanthosis nigricans as a risk factor for non-insulin dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

Plasma fibrinogen: a new factor of the metabolic syndrome. A population-based study.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

Do non-insulin-dependent diabetes mellitus and cardiovascular disease share common antecedents?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

The assessment of insulin resistance in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

Insulin sensitivity in subjects with type 2 diabetes. Relationship to cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

How to measure insulin sensitivity

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

How good a marker is insulin level for insulin resistance?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

Undiagnosed NIDDM: clinical and public health issues.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

American Diabetes Association annual meeting 1996: the etiology of type II diabetes, obesity, and the treatment of type II diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

Epidemiology of Diabetes and its Macrovascular Manifestations in Pacific Populations: The Medical Effects of Social Progress

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

Haemostatic variables associated with diabetes and its complications

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

Increased plasma levels of immunoreactive endothelin and von Willebrand factor in NIDDM patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

Features of syndrome X in first-degree relatives of NIDDM patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

Parental history of diabetes is associated with increased cardiovascular risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

Obesity, insulin resistance, and its link to non-insulin-dependent diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

Hyperglycaemic siblings of Type II (non-insulin-dependent) diabetic patients have increased PAI-1, central obesity and insulin resistance compared with their paired normoglycaemic sibling.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

Emerging epidemic of type 2 diabetes in youth

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

Predictability of childhood adiposity and insulin for developing insulin resistance syndrome (syndrome X) in young adulthood: the Bogalusa Heart Study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

Low-density lipoprotein particle size, central obesity, cardiovascular fitness, and insulin resistance syndrome markers in obese youths

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

Insulin sensitivity and blood pressure in black and white children

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

Pathogenesis of skeletal muscle insulin resistance in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

Pathogenesis of type 2 (non-insulin dependent) diabetes mellitus: a balanced overview

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

Central role of the adipocyte in the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

Pretranslational suppression of a glucose transporter protein causes insulin resistance in adipocytes from patients with non-insulin-dependent diabetes mellitus and obesity

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

Effects of fat on glucose uptake and utilization in patients with non-insulin-dependent diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

Tumor necrosis factor alpha and insulin resistance in obese type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

The role of the novel adipocyte-derived hormone adiponectin in human disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

Interleukin-6 as a central mediator of cardiovascular risk associated with chronic inflammation, smoking, diabetes, and visceral obesity: down-regulation with essential fatty acids, ethanol and pentoxifylline

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

The Importance of -Cell Failure in the Development and Progression of Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

Relationship between obesity, insulin resistance, and coronary heart disease risk

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

Intensive lifestyle changes are necessary to improve insulin sensitivity: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

Smoking cessation improves insulin sensitivity in healthy middle-aged men.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

1 reference

7 January 2021

Metformin treatment leads to an increase in basal, but not insulin-stimulated, glucose disposal in obese patients with impaired glucose tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

Re-evaluation of a biguanide, metformin: mechanism of action and tolerability

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

Effect of weight change and metformin on fibrinolysis and the von Willebrand factor in obese nondiabetic subjects: the BIGPRO1 Study. Biguanides and the Prevention of the Risk of Obesity

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

Improved endothelial function with metformin in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

Metabolic and additional vascular effects of thiazolidinediones.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

Thiazolidinedione derivatives ameliorate albuminuria in streptozotocin-induced diabetic spontaneous hypertensive rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

PPARgamma agonists inhibit cell growth and suppress the expression of cyclin D1 and EGF-like growth factors in ras-transformed rat intestinal epithelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

Hepatic dysfunction associated with troglitazone

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

An autopsy case of troglitazone-induced fulminant hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

Troglitazone-induced hepatic failure leading to liver transplantation. A case report

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

Clinical evidence of thiazolidinedione-induced improvement of pancreatic beta-cell function in patients with type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

Peroxisome proliferator-activated receptor alpha in metabolic disease, inflammation, atherosclerosis and aging

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

Differential activation of adipogenesis by multiple PPAR isoforms.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

Nonhypoglycemic effects of thiazolidinediones

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

Pioglitazone attenuates basal and postprandial insulin concentrations and blood pressure in the spontaneously hypertensive rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

Blood pressure lowering by pioglitazone. Evidence for a direct vascular effect

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

Pioglitazone attenuates diet-induced hypertension in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS).

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

Effects of glycemic control and other determinants on vascular disease in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

The effects of high- and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

Effect of pioglitazone on blood proinsulin levels in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

Rosiglitazone taken once daily provides effective glycaemic control in patients with Type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

Comparison of effects of thiazolidinediones on cardiovascular risk factors: observations from a clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

Regulation of triglyceride metabolism by PPARs: fibrates and thiazolidinediones have distinct effects

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980242-4

7 January 2021

Epidemiologic studies of diabetes in the Pima Indians

series ordinal

29

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(03)80242-4

20 March 2024

Identifiers

1 reference

8 August 2017

1 reference